Open Beta
TREN
MetriLume
TREN

US marketsINM

SEC-sourced researchBeta

INM

InMed Pharmaceuticals Inc.

Company comparison ↗

Data passport

CIK
0001728328
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
4/6
Filing date
Oct 7, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Annual company data is not available for this record.

INM · Exact amounts and source periods · USD
Period endRevenueFiling date
June 2025No dataSep 9, 2026
June 2026No dataSep 9, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
June 2026—-12,560,850.0000-8,643,513.00003,030,067.00001,955,060.0000Sep 9, 2026
June 2025—-8,162,133.0000-8,099,392.000015,580,040.00002,145,545.0000Sep 9, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
Revenue————
Previous period revenue————
Net incomeNetIncomeLoss-$12.56MJune 2026Sep 9, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$8.64MJune 2026Sep 9, 202610-K
Total assetsAssets$3.03MJune 2026Sep 9, 202610-K
Total liabilitiesLiabilities$1.96MJune 2026Sep 9, 202610-K

New filings

Explore methodology ↗